Pharmaceutical industry body PhRMA has reportedly announced its opposition to California's new drug pricing transparency… Read more
- The ROI of Orphan Drugs: Ensuring Optimal Returns
- PhRMA Calls California Drug Pricing Law 'Unconstitutional'
- ISPOR Announces Rebranding Effort
- Latest MAPS Webinar Now Available to Stream Free
- OIG Inching Closer to Safe Haven for Value-Based Contracts
- What's in the Pipeline for Anti-Epilepsy Market?
- MMIT Offers Detailed Look at MS Treatments
- What's in Store for Humana after the CVS-Aetna Merger?
- RTI Health Solutions Breaks Down ISPOR/ISPE RWE Guidelines
- Should the U.S. Take Notes on Drug Prices?
According to a Pink Sheet report, the Office of Inspector General could be moving closer to safe haven for value-based payments. And although… Read more
MMIT in its weekly "Trends that Matter" series offers an in-depth look at recent trends regarding multiple sclerosis treatments. Analysis by MMIT… Read more
Orphan drugs are at the forefront of medical science and offer a chance for the pharma industry to make a real difference to people's lives; there's… Read more
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will soon have a new look. ISPOR CEO and Executive Director Nancy Berg… Read more
The Medical Affairs Professional Society announced its latest webinar, titled "The United States Health Care System," is now available to stream for… Read more